{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:23:38Z","timestamp":1785284618354,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ijrobp.2017.10.053","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T15:17:22Z","timestamp":1509981442000},"page":"670-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-7809","authenticated-orcid":false,"given":"James","family":"Laird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Chelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiji","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-8585","authenticated-orcid":false,"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.10.053_bib1","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2278::AID-CNCR25>3.0.CO;2-U","article-title":"Langerhans cell histiocytosis: Diagnosis, natural history, management, and outcome","volume":"85","author":"Howarth","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib2","first-page":"122","article-title":"Langerhans cell histiocytosis: Emerging insights and clinical implications","volume":"30","author":"Zinn","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.13247","article-title":"Progress in understanding the pathogenesis of Langerhans cell histiocytosis: Back to Histiocytosis X?","volume":"169","author":"Berres","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib4","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.20425","article-title":"Risk factors for diabetes insipidus in Langerhans cell histiocytosis","volume":"46","author":"Grois","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/(SICI)1096-911X(199612)27:6<540::AID-MPO6>3.0.CO;2-L","article-title":"Langerhans cell histiocytosis in the adult","volume":"27","author":"Malpas","year":"1996","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00003086-200010000-00027","article-title":"Langerhans' cell histiocytosis in patients older than 21 years","volume":"379","author":"Islinger","year":"2000","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1067\/mpd.2001.111331","article-title":"A randomized trial of treatment for multisystem Langerhans' cell histiocytosis","volume":"138","author":"Gadner","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib9","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","article-title":"Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification","volume":"111","author":"Gadner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/mpo.2950230203","article-title":"Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 study group","volume":"23","author":"Gadner","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/COC.0b013e318281d6ce","article-title":"Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis","volume":"37","author":"Kotecha","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1200\/JCO.1996.14.7.2073","article-title":"Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco","volume":"14","author":"Willis","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mpo.2950180203","article-title":"Radiation therapy in the management of Langerhans cell histiocytosis","volume":"18","author":"Selch","year":"1990","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00066-006-1630-9","article-title":"Radiotherapy of Langerhans' cell histiocytosis: Results and implications of a national patterns-of-care study","volume":"182","author":"Olschewski","year":"2006","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/0360-3016(79)90556-X","article-title":"Radiation therapy in patients with histiocytosis: Management of diabetes insipidus and bone lesions","volume":"5","author":"Greenberger","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ctrv.2010.02.012","article-title":"Langerhans cell histiocytosis: Current concepts and treatments","volume":"36","author":"Abla","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","article-title":"Management of adult patients with Langerhans cell histiocytosis: Recommendations from an expert panel on behalf of Euro-Histio-Net","volume":"8","author":"Girschikofsky","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib19","series-title":"Common Terminology Criteria for Adverse Events v4.0","year":"2009"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0936-6555(05)80770-8","article-title":"Histiocytosis X: Does radiotherapy still have a role?","volume":"4","author":"el-Sayed","year":"1992","journal-title":"Clin Oncology (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/01.SMJ.0000146548.89694.8A","article-title":"Radiotherapy dose fractionation in pediatric Langerhans cell histiocytosis","volume":"97","author":"Jahraus","year":"2004","journal-title":"South Med J"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/1748-717X-8-233","article-title":"Radiotherapy in Langerhans cell histiocytosis - a rare indication in a rare disease","volume":"8","author":"Kriz","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/mpo.2950160407","article-title":"Radiation therapy in soft-tissue lesions in histiocytosis X (Langerhans' cell histiocytosis)","volume":"16","author":"Gramatovici","year":"1988","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/archderm.1991.01680090109014","article-title":"Primary cutaneous Langerhans cell histiocytosis in an adult","volume":"127","author":"Lichtenwald","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib25","first-page":"13","article-title":"An unusual case of adult disseminated cutaneous Langerhans cell histiocytosis","volume":"12","author":"Moravvej","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib26","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-12-417028-5.00005-3","article-title":"Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases","volume":"120","author":"Berres","year":"2013","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib30","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijrobp.2017.10.053_bib31","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy","volume":"34","author":"Heritier","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617340683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617340683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:41:53Z","timestamp":1759743713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617340683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0360301617340683"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.10.053","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.10.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}